Amantadine in the treatment of pathological gambling: A case report

Frontiers in Psychiatry

Volumn 3, Issue NOV, 2012, Pages

  Pettorruso, Mauro ^a   Martinotti, Giovanni ^b   Di Nicola, Marco ^a   Onofrj, Marco ^b   Di Giannantonio, Massimo ^b   Conte, Gianluigi ^a   Janiri, Luigi ^a  

^a CATHOLIC UNIVERSITY   (Italy)

^b UNIVERSITY OF CHIETI   (Italy)

Author keywords

Addiction; Amantadine; Dopamine; Glutamate; Glutamatergic drugs; Pathological gambling; Treatment

Indexed keywords

AMANTADINE; ESCITALOPRAM; PREGABALIN; TRAZODONE;

ADULT; ALCOHOL WITHDRAWAL; ARTICLE; CASE REPORT; DOPAMINERGIC SYSTEM; DOSE RESPONSE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG TOLERABILITY; DSM-IV; HAMILTON SCALE; HUMAN; ICD-10; MAJOR DEPRESSION; MALE; PATHOLOGICAL GAMBLING; REHABILITATION CARE; SLEEP DISORDER; TREATMENT OUTCOME; YOUNG MANIA RATING SCALE;

EID: 84870921510     PISSN: None     EISSN: 16640640     Source Type: Journal    
DOI: 10.3389/fpsyt.2012.00102     Document Type: Article

References (47)

1. Alterman, A. I., Droba, M., Antelo, R. E., Cornish, J. W., Sweeney, K. K., Parikh, G. A., et al. (1992). Amantadine may facilitate detoxification of cocaine addicts. Drug Alcohol Depend. 31, 19-29.
2. American Psychiatric Association. (2000). Diagnostic and Statistical Manual of Mental Disorders, 4th Edn, Text Revision (DSM-IV-TR). Washington, DC: American Psychiatric Press.
3. Black, D. W., Arndt, S., Coryell, W. H., Argo, T., Forbush, K. T., Shaw, M. C., et al. (2007). Bupropion in the treatment of pathological gambling: a randomized, double-blind, placebocontrolled, flexible-dose study. J. Clin. Psychopharmacol. 27, 143-150.
4. Blanchet,P. J.,Metman,L.V.,and Chase, T. N. (2003). Renaissance of amantadine in the treatment of Parkinson's disease. Adv. Neurol. 91, 251-257.
5. Chuhma, N., Zhang, H., Masson, J., Zhuang, X., Sulzer, D., Hen, R., et al. (2004). Dopamine neurons mediate a fast excitatory signal via their glutamatergic synapses. J. Neurosci. 24, 972-981.
6. Cloninger, C. R., Svrakic, D. M., and Przybeck, T. R. (1993). A psychobiological model of temperament and character. Arch. Gen. Psychiatry 50, 975-990.
7. Davies, W. L., Grunert, R. R., Haff, R. F., McGahen, J. W., Neumayer, E. M., Paulshock, M., et al. (1964). Antiviral activity of 1-adamantanamine (amantadine). Science 144, 862-863.
8. de Ruiter, M. B., Veltman, D. J., Goudriaan, A. E., Oosterlaan, J., Sjoerds, Z., and Van den Brink, W. (2009). Response perseveration and ventral prefrontal sensitivity to reward and punishment in male problem gamblers and smokers. Neuropsychopharmacology 34, 1027-1038.
9. Di Nicola, M., Martinotti, G., Tedeschi, D., Frustaci, A., Mazza, M., Sarchiapone, M., et al. (2010). Pregabalin in outpatient detoxification of subjects with mild-to-moderate alcohol withdrawal syndrome. Hum. Psychopharmacol. 25, 268-275.
10. Diana, M. (2011). The dopamine hypothesis of drug addiction and its potential therapeutic value. Front. Psychiatry 2:64. doi:10.3389/fpsyt.2011.00064
11. El Mestikawy, S., Wallén-Mackenzie, A., Fortin, G. M., Descarries, L., and Trudeau, L. E. (2011). From glutamate co-release to vesicular synergy: vesicular glutamate transporters. Nat. Rev. Neurosci. 12, 204-216.
12. Everitt, B. J., and Robbins, T. W. (2005). Neural systems of reinforcement for drug addiction: from actions to habits to compulsion. Nat. Neurosci. 8, 1481-1489.
13. Fasano, A., Ricciardi, L., Pettorruso, M., and Bentivoglio, A. R. (2011). Management of punding in Parkinson's disease: an open-label prospective study. J. Neurol. 258, 656-660.
14. Fisher, K., Coderre, T. J., and Hagen, N. A. (2000). Targeting the N-methylD-aspartate receptor for chronic pain management. Preclinical animal studies, recent clinical experience and future research directions. J. Pain Symptom Manage. 20, 358-373.
15. Giannini, A. J., Folts, D. J., Feather, J. N., and Sullivan, B. S. (1989). Bromocriptine and amantadine in cocaine detoxification. Psychiatry Res. 29, 11-16.
16. Grant, J. E., Chamberlain, S. R., Odlaug, B. L., Potenza, M. N., and Kim, S. W. (2010). Memantine shows promise in reducing gambling severity and cognitive inflexibility in pathological gambling: a pilot study. Psychopharmacology (Berl.) 212, 603-612.
17. Grant, J. E., Kim, S. W., and Odlaug, B. L. (2007). N-acetyl cysteine, a glutamate-modulating agent, in the treatment of pathological gambling: a pilot study. Biol. Psychiatry 62, 652-657.
18. Hamilton, M. (1960). A rating scale for depression. J. Neurol. Neurosurg. Psychiatr. 23, 56-62.
19. Hodgins, D. C., Stea, J. N., and Grant, J. E. (2011). Gambling disorders. Lancet 378, 1874-1884.
20. Hubsher, G., Haider, M., and Okun, M. S. (2012). Amantadine: the journey from fighting flu to treating Parkinson disease. Neurology 78, 1096-1099.
21. Joutsa, J., Johansson, J., Niemelä, S., Ollikainen, A., Hirvonen, M. M., Piepponen, P., et al. (2012). Mesolimbic dopamine release is linked to symptom severity in pathological gambling. Neuroimage 60, 1992-1999.
22. Kalivas, P. W. (2009). The glutamate homeostasis hypothesis of addiction. Nat. Rev. Neurosci. 10,561-572.
23. Kalivas, P. W., and Volkow, N. D. (2011). New medications for drug addiction hiding in glutamatergic neuroplasticity. Mol. Psychiatry 16, 974-986.
24. Kampman, K. M., Dackis, C., Lynch, K. G., Pettinati, H., Tirado, C., Gariti, P., et al. (2006). A double-blind, placebo-controlled trial of amantadine, propranolol, and their combination for the treatment of cocaine dependence in patients with severe cocaine withdrawal symptoms. Drug Alcohol Depend. 85, 129-137.
25. Kampman, K. M., Volpicelli, J. R., Alterman, A. I., Cornish, J., and O'Brien, C. P. (2000). Amantadine in the treatment of cocainedependent patients with severe withdrawal symptoms. Am. J. Psychiatry 157, 2052-2054.
26. Kim, S. W., Grant, J. E., Potenza, M. N., Blanco, C., and Hollander, E. (2009). The Gambling Symptom Assessment Scale (G-SAS): a reliability and validity study. Psychiatry Res. 166, 76-84.
27. Linnet, J., Mouridsen, K., Peterson, E., Møller, A., Doudet, D. J., and Gjedde, A. (2012). Striatal dopamine release codes uncertainty in pathological gambling. Psychiatry Res. doi:10. 1016/j.pscychresns.2012.04.012
28. Martinotti, G., Mandelli, L., Di Nicola, M., Serretti, A., Fossati, A., Borroni, S., et al. (2008). Psychometric characteristic of the Italian version of the Temperament and Character Inventory-revised, personality, psychopathology, and attachment styles. Compr. Psychiatry 49, 514-522.
29. Melis, M., Spiga, S., and Diana, M. (2005). The dopamine hypothesis of drug addiction: hypodopaminergic state. Int. Rev. Neurobiol. 63, 101-154.
30. Meythaler, J. M., Brunner, R. C., Johnson, A., and Novack, T. A. (2002). Amantadine to improve neurorecovery in traumatic brain injuryassociated diffuse axonal injury: a pilot double-blind randomized trial. J. Head Trauma Rehabil. 17, 300-313.
31. Olive, M. F., Cleva, R. M., Kalivas, P. W., and Malcolm, R. J. (2012). Glutamatergic medications for the treatment of drug and behavioral addictions. Pharmacol. Biochem. Behav. 100, 801-810.
32. Pappa, S., Tsouli, S., Apostolou, G., Mavreas, V., and Konitsiotis, S. (2010). Effects of amantadine on tardive dyskinesia: a randomized, double-blind, placebo-controlled study. Clin. Neuropharmacol. 33, 271-275.
33. Patton, J. H., Stanford, M. S., and Barratt, E. S. (1995). Factor structure of the Barratt impulsiveness scale. J. Clin. Psychol. 51, 768-774.
34. Petry, N. M. (2010). Pathological gambling and the DSM-V. Int. Gambl. Stud. 10, 113-115.
35. Potenza, M. N. (2008). The neurobiology of pathological gambling and drug addiction:an overview and new findings. Philos. Trans. R. Soc. Lond. B Biol. Sci. 363, 3181-3189.
36. Rajput, A. H., Rajput, A., Lang, A. E., Kumar, R., Uitti, R. J., and Galvez-Jimenez, N. (1998). New use for an old drug: amantadine benefits levodopa-induced dyskinesia. Mov. Disord. 13, 851.
37. Reuter, J., Raedler, T., Rose, M., Hand, I., Gläscher, J., and Büchel, C. (2005). Pathological gambling is linked to reduced activation of the mesolimbic reward system. Nat. Neurosci. 8, 147-148.
38. Sawada, H., Oeda, T., Kuno, S., Nomoto, M., Yamamoto, K., Yamamoto, M., et al. (2010). Amantadine for dyskinesias in Parkinson's disease: a randomized controlled trial. PLoS ONE 5, e15298. doi:10.1371/journal.pone.0015298
39. Schwab, R. S., England, A. C. Jr., Poskanzer, D. C., and Young, R. R. (1969). Amantadine in the treatment of Parkinson's disease. JAMA 208, 1168-1170.
40. Shoptaw, S., Kintaudi, P. C., Charuvastra, C., and Ling, W. (2002). A screening trial of amantadine as a medication for cocaine dependence. Drug Alcohol Depend. 66, 217-224.
41. Stromberg, U., Svensson, T. H., and Waldeck, B. (1970). On the mode of action of amantadine. J. Pharm. Pharmacol. 22, 959-962.
42. Takahashi, T., Yamashita, H., Zhang, Y. X., and Nakamura, S. (1996). Inhibitory effect of MK-801 on amantadine-induced dopamine release in the rat striatum. Brain Res. Bull. 41, 363-367.
43. Thomas, A., Bonanni, L., Gambi, F., Di Iorio, A., and Onofrj, M. (2010). Pathological gambling in Parkinson disease is reduced by amantadine. Ann. Neurol. 68, 400-404.
44. Voon, V., Fernagut, P. O., Wickens, J., Baunez, C., Rodriguez, M., Pavon, N., et al. (2009). Chronic dopaminergic stimulation in Parkinson's disease: from dyskinesias to impulse control disorders. Lancet Neurol. 8, 1140-1149.
45. Weddington, W. W. Jr., Brown, B. S., Haertzen, C. A., Hess, J. M., Mahaffey, J. R., Kolar, A. F., et al. (1991). Comparison of amantadine and desipramine combined with psychotherapy for treatment of cocaine dependence. Am. J. Drug Alcohol Abuse 17, 137-152.
46. Young, R. C., Biggs, J. T., Ziegler, V. E., and Meyer, D. A. (1978). A rating scale for mania: reliability, validity and sensitivity. Br. J. Psychiatry 133, 429-435.
47. Zack, M., and Poulos, C. X. (2007). A D2 antagonist enhances the rewarding and priming effects of a gambling episode in pathological gamblers. Neuropsychopharmacology 32, 1678-1686